Leading global pharmaceutical company AbbVie Inc. (NYSE: ABBV) researches, develops, and sells innovative drugs. The company was formed in 2013 after separating from Abbott Laboratories. It is known for its immunology drugs and is currently focused on growing sales from its newer treatments, Skyrizi and Rinvoq, to replace revenue from its former blockbuster drug, Humira.
On April 20, 2026, Canaccord Genuity initiated coverage on AbbVie with a "Buy" rating and set a price target of $262.00. At the time of the rating, the stock was trading at $203.71. This new price target represents a potential upside of 28.61% for the stock from its price when the rating was published.
This positive outlook is supported by the strong performance of its newer drugs. Skyrizi and Rinvoq are reportedly generating revenue that exceeds expectations, easing concerns over the patent expiration of Humira. As highlighted by Zacks Investment Research, the strength of the company's drug pipeline is a key factor shaping its future.
Despite a 7.03% year-to-date decline, some analysts view the stock's current price as an opportunity. As noted by The Motley Fool, AbbVie has pulled back about 13% from its record high of $238.71. This recent dip is seen by some as a good entry point for long-term investors.
A key factor for investors is the company's status as a "Dividend King," meaning it has a long history of increasing its dividend. The quarterly dividend has grown from $0.40 in 2013 to $1.73 today. This results in an annual dividend of $6.65 per share, providing a 3.19% dividend yield at current prices.
